Sunday, September 26, 2021

Transcenta Received IND Clearance from NMPA of its Anti-sclerostin Monoclonal Antibody TST002

SUZHOU, China, Sept. 26, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it received IND...



from PR Newswire: https://ift.tt/3lYfdlj

No comments:

Post a Comment